scholarly journals Development and Validation of a Medication Selection Model Under Clinical Application of Renin-Angiotensin Inhibitor Combined with Calcium Channel Blocker for Hypertension Patients

2020 ◽  
Vol 26 ◽  
Author(s):  
Dongsheng Hong ◽  
Wendan Shi ◽  
Xiaoyang Lu ◽  
Yan Lou ◽  
Lu Li
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Clinical Application ◽  
Channel Blocker ◽  
Selection Model ◽  
Renin Angiotensin ◽  
Medication Selection ◽  
Development And Validation

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema

2011 ◽  
Vol 124 (2) ◽  
pp. 128-135 ◽  
Author(s):  
Harikrishna Makani ◽  
Sripal Bangalore ◽  
Jorge Romero ◽  
Omar Wever-Pinzon ◽  
Franz H. Messerli
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Peripheral Edema ◽  
Renin Angiotensin

scholarly journals Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19

2021 ◽  
Author(s):  
Jordan Loader ◽  
Erik Lampa ◽  
Stefan Gustafsson ◽  
Thomas Cars ◽  
Johan Sundström
Keyword(s):  
Primary Prevention ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Thiazide Diuretic ◽  
Channel Blocker ◽  
Renin Angiotensin Aldosterone System ◽  
Policy Makers ◽  
Renin Angiotensin ◽  
Propensity Score Methods ◽  
Raas Inhibitors

Background Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin‐angiotensin aldosterone system (RAAS) inhibitor use and COVID‐19 remain unknown. Accordingly, this study tested the hypothesis that RAAS inhibitors influence the summation effect of COVID‐19 and its progression to severe outcomes. Methods and Results This nationwide cohort study compared all residents of Sweden, without prior cardiovascular disease, in monotherapy (as of January 1, 2020) with a RAAS inhibitor to those using a calcium channel blocker or a thiazide diuretic. Comparative cohorts were balanced using machine‐learning‐derived propensity score methods. Of 165 355 people in the analysis (51% women), 367 were hospitalized or died with COVID‐19 (246 using a RAAS inhibitor versus 121 using a calcium channel blocker or thiazide diuretic; Cox proportional hazard ratio [HR], 0.97; 95% CI, 0.74–1.27). When each outcome was assessed separately, 335 people were hospitalized with COVID‐19 (HR, 0.92; 95% CI, 0.70–1.22), and 64 died with COVID‐19 (HR, 1.22; 95% CI, 0.68–2.19). The severity of COVID‐19 outcomes did not differ between those using a RAAS inhibitor and those using a calcium channel blocker or thiazide diuretic (ordered logistic regression odds ratio, 1.01; 95% CI, 0.89–1.14). Conclusions Despite potential limitations, this study is among the best available evidence that RAAS inhibitor use in primary prevention does not increase the risk of severe COVID‐19 outcomes; presenting strong data from which scientists and policy makers alike can base, with greater confidence, their current position on the safety of using RAAS inhibitors during the COVID‐19 pandemic.

Sign in / Sign up

Export Citation Format

Share Document